Design Therapeutics (DSGN) Total Current Liabilities (2020 - 2026)

Design Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $10.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 23.73% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $10.2 million (up 23.73% YoY), while the FY2025 annual figure was $13.1 million, up 54.28% from the prior year.
• Total Current Liabilities came in at $10.2 million for Q1 2026 at Design Therapeutics, down from $13.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $13.1 million in Q4 2025 to a low of $5.5 million in Q1 2022.
• A 5-year average of $9.3 million and a median of $9.0 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 116.98% in 2022 and slumped 47.3% in 2024, its largest moves.
• Design Therapeutics' Total Current Liabilities stood at $10.8 million in 2022, then dropped by 10.71% to $9.6 million in 2023, then slipped by 12.06% to $8.5 million in 2024, then surged by 54.28% to $13.1 million in 2025, then retreated by 21.95% to $10.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $10.2 million, $13.1 million, and $11.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison